Funder: National Institutes of Health

Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | June 5, 2026 (New) | July 5, 2026 (Renewal/Resubmission/Revision) | October 5, 2026 (New) | November 5, 2026 (Renewal/Resubmission/Revision) | February 5, 2027 (New) | March 5, 2027 (Renewal/Resubmission/Revision) | June 5, 2027 (New) | July 5, 2027 (Renewal/Resubmission/Revision) | October 5, 2027 (New) | November 5, 2027 (Renewal/Resubmission/Revision)

Funding Amounts: No budget cap; budgets must reflect actual needs. Maximum project period: 5 years.

Summary: Supports research to understand, characterize, and mitigate long-term adverse effects of cancer therapies through mechanistic, translational, and clinical studies.

Key Information: Both U.S. and non-U.S. organizations are eligible; clinical trials are optional; applications requesting ≥$500,000 direct costs in any year require prior contact with NIH.